Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Key Efficacy Comparison Year 1 Outcomes: For chronic weight management in adults without diabetes, tirzepatide 15 mg achieved a mean 22.5% total body weight reduction in SURMOUNT-1 (N Engl J Med, 2022), while semaglutide 2.4 mg delivered approximately 15% in the STEP program
Please consult first with Jivas Weight Loss Specialist or your personal health care provider to discuss if semaglutide is the best treatment option for you
Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 trial extension)
Methods This real-world retrospective cohort study used Truveta Data, which includes de-identified electronic health record (EHR) data from more than 120 million patients across the US
Kidney function, liver function, and gastrointestinal tolerance must be assessed before progressing to higher doses
US$ 23.57
US$ 22.92
US$ 27.85
US$ 23.58
